1Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, et al. (2006) Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. European heart journal. 27:949–53.
2Lip GYH, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, (2014) et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). European heart journal 35:3365–76.
3Ang R, Earley MJ (2016) The role of catheter ablation in the management of atrial fibrillation. Clinical medicine (London, England) 16:267–71.
4Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ et al. (2012) HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 14:528–606.
5Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. (2016) ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 18:1609–78.
6Bertaglia E, Senatore G, Michieli L de, Simone A de, Amellone C, Ferretto S et al. (2016) Twelve-year follow-up of catheter ablation for atrial fibrillation: A prospective, multicenter, randomized study. Heart rhythm.
7Nielsen JC, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Pehrson SM et al. (2017) Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial. Heart (British Cardiac Society) 103:368–76.
8Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D et al. (2016) Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. Circulation 133:1637–44.
9Wilber DJ, Pappone C, Neuzil P, Paola A de, Marchlinski F, Natale A et al. (2010) Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 303:333–40.
10Mont L, Bisbal F, Hernandez-Madrid A, Perez-Castellano N, Vinolas X, et al. (2014) Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). European heart journal 35:501–7.
11Friberg L, Tabrizi F, Englund A (2016) Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: Data from Swedish health registries. European heart journal 37:2478–87.
12Reynolds MR, Gunnarsson CL, Hunter TD, Ladapo JA, March JL, et al. (2012) Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: results of a propensity-matched analysis. Circulation. Cardiovascular quality and outcomes 5:171–81.
13Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck K-H, Vardas P et al. (2013) Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. American heart journal 166:442–8.
14Shi L-Z, Heng R, Liu S-M, Leng F-Y (2015) Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: A meta-analysis of randomized controlled trials. Experimental and therapeutic medicine 10:816–22.
15Hunter RJ, McCready J, Diab I, Page SP, Finlay M, Richmond L et al. (2012) Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart (British Cardiac Society) 98:48–53.
16Chang C-H, Lin J-W, Chiu F-C, Caffrey JL, Wu L-C, Lai M-S (2014) Effect of radiofrequency catheter ablation for atrial fibrillation on morbidity and mortality: a nationwide cohort study and propensity score analysis. Circulation. Arrhythmia and electrophysiology 7:76–82.
17Weerasooriya R, Jais P, Le Heuzey J-Y, Scavee C, Choi K-J, Macle L et al. (2003) Cost analysis of catheter ablation for paroxysmal atrial fibrillation. Pacing and clinical electrophysiology. PACE 26:292–294.
18Aronsson M, Walfridsson H, Janzon M, Walfridsson U, Nielsen JC, Hansen PS et al. (2015) The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 17:48–55.
19van Brabandt H, Neyt M, Devos C (2013) Effectiveness of catheter ablation of atrial fibrillation in Belgian practice: a cohort analysis on administrative data. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 15:663–668.
20Hoffmann F (2009) Review on use of German health insurance medication claims data for epidemiological research. Pharmacoepidemiology and drug safety 18:349–356.
21Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, et al. (2019) Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA.
22Packer M (2019) Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation. European heart journal 40:1873–9.